fda warning letters compounded semaglutide tirzepatide september 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Issues Warning Letters to

Red asterisks indicate significance of GLP-1RA/Tesaglitazar over Vhcl, blue asterisks indicate significance of Tesaglitazar over Vhcl

Those who complained of gastrointestinal adverse effects were also more likely to discontinue use as well as those who lost more weight

Many patients report less hunger and increased fullness within this window, which is actually ideal for avoiding heavy eating sessions

These compounds can support the building blocks your body needs to preserve lean muscle mass, that may be helpful during periods of calorie restriction

While this provides important baseline protection, it leaves gaps: entire drug classes that athletes could test positive for despite using "certified" products

doi: 10.1016/j.jacc.2023.12.023